IMMUNEERING CORPORATION

Immuneering reports preclinical results on Atebimetinib in Cancer Research: the dual MEK inhibitor showed antitumor activity in KRAS-, NRAS- and BRAF-mutated models and resists RAF-mediated bypass signaling. In direct comparisons, Atebimetinib inhibited tumor growth more strongly than binimetinib and lowered pERK and pMEK levels, with a short-lived, deep cyclic inhibition mechanism described. In a cachexia model, treated animals’ body weight remained stable for longer. Immuneering is recruiting patients for the phase 3 MAPKeeper 301 study and plans to start a phase 2 study in the second half of the year combining Atebimetinib with Libtayo in RAS-mutant NSCLC. » Más en de.investing.com

Immuneering shares jumped about 12.5% in after‑hours trading following publication of updated phase‑2a data for atebimetinib in combination with modified gemcitabine/nab‑paclitaxel. In an expanded cohort of 55 first‑line patients, median overall survival was 17.3 months; serious treatment‑related events ≥Grade 3 occurred mainly as anemia (16%) and neutropenia (18%) and were attributed to the chemotherapy. The approval‑relevant phase‑3 study MAPKeeper 301 is still recruiting and is on track to administer the first dose to the first patient in mid‑2026. Full study data will be presented on June 1, 2026, at the annual meeting of the American Society of Clinical Oncology; an investor conference call is scheduled. » Más en de.investing.com

Immuneering is presenting survival data at the ASCO annual meeting from a Phase 2a study in which 55 patients with metastatic pancreatic cancer were treated in first-line therapy with atebimetinib plus modified gemcitabine/nab‑paclitaxel (data cutoff April 2026). The company is currently conducting the regulatory Phase 3 study MAPKeeper 301 and expects to enroll the first patient by mid‑2026. One third‑line patient on atebimetinib monotherapy has been progression‑free for 27 months with an 85% tumor reduction; genetic analyses revealed rare acquired MAPK alterations. For Q1 2026 Immuneering reported a net loss of $13.5 million and cash and cash equivalents of $198.6 million; the company considers the cash runway through 2029 to be sufficient. » Más en de.investing.com